Literature DB >> 9733896

Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase.

P J King1, W E Robinson.   

Abstract

L-Chicoric acid is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase in vitro and of HIV-1 replication in tissue culture. Following 3 months of selection in the presence of increasing concentrations of L-chicoric acid, HIV-1 was completely resistant to the compound. Introduction of the mutant integrase containing a single glycine-to-serine amino acid change at position 140 into the native, L-chicoric acid-sensitive virus demonstrated that this change was sufficient to confer resistance to L-chicoric acid. These results confirm through natural selection previous biochemical studies showing that L-chicoric acid inhibits integrase and that the drug is likely to interact at residues near the catalytic triad in the integrase active site.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733896      PMCID: PMC110234     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases.

Authors:  J Kulkosky; K S Jones; R A Katz; J P Mack; A M Skalka
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

2.  Analysis of mutations in the integration function of Moloney murine leukemia virus: effects on DNA binding and cutting.

Authors:  M J Roth; P Schwartzberg; N Tanese; S P Goff
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release.

Authors:  W E Robinson; D C Montefiori; D H Gillespie; W M Mitchell
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

5.  Anti-AIDS agents, 1. Isolation and characterization of four new tetragalloylquinic acids as a new class of HIV reverse transcriptase inhibitors from tannic acid.

Authors:  M Nishizawa; T Yamagishi; G E Dutschman; W B Parker; A J Bodner; R E Kilkuskie; Y C Cheng; K H Lee
Journal:  J Nat Prod       Date:  1989 Jul-Aug       Impact factor: 4.050

6.  Anti-AIDS agents, 2: Inhibitory effects of tannins on HIV reverse transcriptase and HIV replication in H9 lymphocyte cells.

Authors:  G Nonaka; I Nishioka; M Nishizawa; T Yamagishi; Y Kashiwada; G E Dutschman; A J Bodner; R E Kilkuskie; Y C Cheng; K H Lee
Journal:  J Nat Prod       Date:  1990 May-Jun       Impact factor: 4.050

7.  Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.

Authors:  B McDougall; P J King; B W Wu; Z Hostomsky; M G Reinecke; W E Robinson
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.

Authors:  Z Gu; Q Gao; X Li; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

Authors:  D C Montefiori; W E Robinson; S S Schuffman; W M Mitchell
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  16 in total

1.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

Authors:  Mathieu Métifiot; Kasthuraiah Maddali; Alena Naumova; Xuemin Zhang; Christophe Marchand; Yves Pommier
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

2.  Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.

Authors:  Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid.

Authors:  Ryan Reinke; Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

4.  Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.

Authors:  Valery Fikkert; Bénédicte Van Maele; Jo Vercammen; Anke Hantson; Barbara Van Remoortel; Martine Michiels; Cristina Gurnari; Christophe Pannecouque; Marc De Maeyer; Yves Engelborghs; Erik De Clercq; Zeger Debyser; Myriam Witvrouw
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.

Authors:  Nick Shkriabai; Sachindra S Patil; Sonja Hess; Scott R Budihas; Robert Craigie; Terrence R Burke; Stuart F J Le Grice; Mamuka Kvaratskhelia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.

Authors:  Deborah J Lee; W E Robinson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Mechanistic and pharmacological analyses of HIV-1 integration.

Authors:  Alan Engelman
Journal:  Methods       Date:  2009-04       Impact factor: 3.608

8.  An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule.

Authors:  Jacques J Kessl; Jocelyn O Eidahl; Nikolozi Shkriabai; Zhuojun Zhao; Christopher J McKee; Sonja Hess; Terrence R Burke; Mamuka Kvaratskhelia
Journal:  Mol Pharmacol       Date:  2009-07-28       Impact factor: 4.436

9.  Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.

Authors:  Gregg S Jones; Fang Yu; Ameneh Zeynalzadegan; Joseph Hesselgesser; Xiaowu Chen; James Chen; Haolun Jin; Choung U Kim; Matthew Wright; Romas Geleziunas; Manuel Tsiang
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

10.  Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.

Authors:  Isabelle Malet; Olivier Delelis; Marc-Antoine Valantin; Brigitte Montes; Cathia Soulie; Marc Wirden; Luba Tchertanov; Gilles Peytavin; Jacques Reynes; Jean-François Mouscadet; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.